UltraGreen.ai Q3 revenue up 43.9% but expects FY2026 revenue to fall short of guidance
It targets new dividend payout of at least 30% of earnings; plans share buyback of up to US$30 million
UltraGreen.ai, a Singapore-based medtech company, saw a 43.9% increase in Q3 2026 revenue to US$44.6 million from US$31 million in Q3 2025. The growth was driven by a 47% increase from the US market and a 32% rise in revenue from the rest of the world. The company expects its FY2026 revenue to fall short of guidance, which was previously forecasted to be between US$175 million and US$185 million.
CEO Ravinder Sajwan highlighted the challenges posed by competing ICG products and pricing pressures in the US market. UltraGreen.ai is responding by engaging closer with customers and distribution partners, expanding its product offerings, and managing costs. The company plans to relaunch its generic ICG product and explore opportunities in new clinical settings.
UltraGreen.ai has also received regulatory approvals in Europe and South Africa, expanding its presence to 42 countries. The board has approved a capital allocation framework that prioritizes reinvestment, dividends, strategic acquisitions, and share buybacks.
Written by urgent.news from The Business Times - Companies & Markets's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
